International Journal of Hematology

, Volume 109, Issue 1, pp 115–124 | Cite as

Risk factors and survival impact of readmission after single-unit cord blood transplantation for adults

  • Yasuko Yamagishi
  • Takaaki KonumaEmail author
  • Yoriko Miwa
  • Maki Oiwa-Monna
  • Susumu Tanoue
  • Masamichi Isobe
  • Koji Jimbo
  • Mai Mizusawa
  • Hatsuko Narita
  • Koji Kobayashi
  • Seiko Kato
  • Satoshi Takahashi
  • Arinobu Tojo
Original Article


Hospital readmissions have been used as a prognostic indicator for patients receiving allogeneic hematopoietic cell transplantation (HCT). However, the impact of readmission during early and mid-phase of cord blood transplantation (CBT) on long-term outcomes has not been fully investigated. We retrospectively analyzed 156 adult patients who received single-unit CBT in our institute. Among this cohort, thirteen patients (8%) were readmitted within 30 days after discharge, and 27 (17%) were readmitted within 90 days after discharge. The most common causes for readmission within 30 and 90 days of discharge were infection, chronic graft-versus-host disease, and relapse. Higher cryopreserved cord blood CD34+ cell count was only significantly associated with lower readmission within 90 days after discharge. The probabilities of overall survival were significantly lower in patients readmitted within 90 days after discharge compared with those who were not readmitted within 90 days after discharge in univariate and multivariate analysis. These data suggest that readmission within 90 days after discharge may have a significant impact on long-term mortality after single-unit CBT.


Readmission Discharge Length of hospital stay Cord blood transplantation Infection 



The authors thank all of the physicians and staff at the hospital and the cord blood banks in Japan for their help in this study.

Compliance with ethical standards

Conflict of interest

The authors declare no competing financial interests.


  1. 1.
    Milano F, Gooley T, Wood B, Woolfrey A, Flowers ME, Doney K, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375(10):944–53.CrossRefGoogle Scholar
  2. 2.
    Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, et al. Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia. Biol Blood Marrow Transplant. 2016;22(2):330–8.CrossRefGoogle Scholar
  3. 3.
    Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104(12):3813–20.CrossRefGoogle Scholar
  4. 4.
    Konuma T, Tsukada N, Kanda J, Uchida N, Ohno Y, Miyakoshi S, et al. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. Am J Hematol. 2016;91(5):E284-92.CrossRefGoogle Scholar
  5. 5.
    Yazaki M, Atsuta Y, Kato K, Kato S, Taniguchi S, Takahashi S, et al. Incidence and risk factors of early bacterial infections after unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2009;15(4):439–46.CrossRefGoogle Scholar
  6. 6.
    Servais S, Lengline E, Porcher R, Carmagnat M, Peffault de Latour R, et al. Long-term immune reconstitution and infection burden after mismatched hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(4):507–17.CrossRefGoogle Scholar
  7. 7.
    Dharmarajan K, Hsieh AF, Lin Z, Bueno H, Ross JS, Horwitz LI, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355–63.CrossRefGoogle Scholar
  8. 8.
    Krumholz HM, Lin Z, Keenan PS, Chen J, Ross JS, Drye EE, et al. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA. 2013;309(6):587–93.CrossRefGoogle Scholar
  9. 9.
    Dharmarajan K, Wang Y, Lin Z, Normand ST, Ross JS, Horwitz LI, et al. Association of changing hospital readmission rates with mortality rates after hospital discharge. JAMA. 2017;318(3):270–8.CrossRefGoogle Scholar
  10. 10.
    Jaing TH, Tsay PK, Yang CP, Hung IJ, Wen YC, Tseng CK. Evaluation of readmission in children receiving allogeneic hematopoietic stem cell transplantation: an institutional experience. Transplant Proc. 2008;40(10):3643–5.CrossRefGoogle Scholar
  11. 11.
    Shulman DS, London WB, Guo D, Duncan CN, Lehmann LE. Incidence and causes of hospital readmission in pediatric patients after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(5):913–9.CrossRefGoogle Scholar
  12. 12.
    Maher OM, Silva JG, Huh WW, Cuglievan B, DePombo A, Kebriaei P, et al. Etiologies and impact of readmission rates in the first 180 days after hematopoietic stem cell transplantation in children, adolescents, and young Adults. J Pediatr Hematol Oncol. 2017;39(8):609–13.CrossRefGoogle Scholar
  13. 13.
    Grant M, Cooke L, Bhatia S, Forman S. Discharge and unscheduled readmissions of adult patients undergoing hematopoietic stem cell transplantation: implications for developing nursing interventions. Oncol Nurs Forum. 2005;32(1):E1–8.CrossRefGoogle Scholar
  14. 14.
    Moya R, Espigado I, Parody R, Carmona M, Márquez F, De Blas JM. Evaluation of readmissions in hematopoietic stem cell transplant recipients. Transplant Proc. 2006;38(8):2591–2.CrossRefGoogle Scholar
  15. 15.
    Bejanyan N, Bolwell BJ, Lazaryan A, Rybicki L, Tench S, Duong H, et al. Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT). Biol Blood Marrow Transplant. 2012;18(6):874–80.CrossRefGoogle Scholar
  16. 16.
    Dignan FL, Potter MN, Ethell ME, Taylor M, Lewis L, Brennan J, et al. High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. Clin Transplant. 2013;27(1):E56–63.CrossRefGoogle Scholar
  17. 17.
    Rauenzahn S, Truong Q, Cumpston A, Goff L, Leadmon S, Evans K, et al. Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20(3):415–20.CrossRefGoogle Scholar
  18. 18.
    Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP 3rd, Glotzbecker B. Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant. 2015;21(3):509–16.CrossRefGoogle Scholar
  19. 19.
    Crombie J, Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP 3rd, et al. Readmissions after umbilical cord blood transplantation and impact on overall survival. Biol Blood Marrow Transplant. 2017;23(1):113–8.CrossRefGoogle Scholar
  20. 20.
    Sundaramurthi T, Wehrlen L, Friedman E, Thomas S, Bevans M. Hematopoietic stem cell transplantation recipient and caregiver factors affecting length of stay and readmission. Oncol Nurs Forum. 2017;44(5):571–9.CrossRefGoogle Scholar
  21. 21.
    Seto A, Atsuta Y, Kawashima N, Ozawa Y, Miyamura K, Kiyoi H. Impact of hospital length of stay on the risk of readmission and overall survival after allogeneic stem cell transplantation. Int J Hematol. 2018;108(3):290–7.CrossRefGoogle Scholar
  22. 22.
    Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367–9.CrossRefGoogle Scholar
  23. 23.
    Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664–71.CrossRefGoogle Scholar
  24. 24.
    Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.CrossRefGoogle Scholar
  25. 25.
    Ballen KK, Joffe S, Brazauskas R, Wang Z, Aljurf MD, Akpek G, et al. Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources. Biol Blood Marrow Transplant. 2014;20(11):1819–27.CrossRefGoogle Scholar
  26. 26.
    Konuma T, Kato S, Oiwa-Monna M, Tanoue S, Ogawa M, Isobe M, et al. Cryopreserved CD34 + cell dose, but not total nucleated cell dose, influences hematopoietic recovery and extensive chronic graft-versus-host disease after single-unit cord blood transplantation in adult patients. Biol Blood Marrow Transplant. 2017;23(7):1142–50.CrossRefGoogle Scholar
  27. 27.
    Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11(7):653–60.CrossRefGoogle Scholar
  28. 28.
    Niehues T, Rocha V, Filipovich AH, Chan KW, Porcher R, Michel G, et al. Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children—a Eurocord analysis. Br J Haematol. 2001;114(1):42–8.CrossRefGoogle Scholar
  29. 29.
    Komanduri KV, St John LS, de Lima M, McMannis J, Rosinski S, McNiece I, et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood. 2007;110(13):4543–51.CrossRefGoogle Scholar
  30. 30.
    Rénard C, Barlogis V, Mialou V, Galambrun C, Bernoux D, Goutagny MP, et al. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children. Br J Haematol. 2011;152(3):322–30.CrossRefGoogle Scholar
  31. 31.
    Kanda J, Chiou LW, Szabolcs P, Sempowski GD, Rizzieri DA, Long GD, et al. Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18(11):1664–76.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Yasuko Yamagishi
    • 1
  • Takaaki Konuma
    • 2
    Email author
  • Yoriko Miwa
    • 1
  • Maki Oiwa-Monna
    • 2
  • Susumu Tanoue
    • 2
  • Masamichi Isobe
    • 2
  • Koji Jimbo
    • 2
  • Mai Mizusawa
    • 2
  • Hatsuko Narita
    • 1
  • Koji Kobayashi
    • 1
  • Seiko Kato
    • 2
  • Satoshi Takahashi
    • 2
  • Arinobu Tojo
    • 2
  1. 1.Department of Nursing, Research Hospital, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  2. 2.Department of Hematology/Oncology, The Institute of Medical ScienceThe University of TokyoTokyoJapan

Personalised recommendations